New Study Provides Key Insights on Dolutegravir Use in Children Receiving Tuberculosis Treatment

Our team contributed to a newly published study in The Lancet HIV on the pharmacokinetics and safety of dolutegravir in children receiving rifampicin for tuberculosis treatment.

The study found that twice-daily dolutegravir in children weighing 20–35 kg achieves therapeutic drug levels, is well tolerated, and leads to high rates of viral suppression. The findings also suggest that once-daily dosing during rifampicin co-administration should be further explored in clinical studies.